Document Detail


Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
MedLine Citation:
PMID:  18824134     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the effects of the angiotensin II receptor blocker (ARB) candesartan and the calcium channel blocker (CCB) amlodipine on the incidence of cardiovascular (CV) events in Japanese high-risk hypertensive patients. After 3.2years follow-up, CV events rate was 17.6-17.7 per 1000 person-years in each group, which was much lower than we expected. Since it has not been known whether the same efficacy of two drugs is sustained beyond the current trial, a longer follow-up period will be needed. The Steering Committee of CASE-J trial decided to extend the trial for 3years as an observational study (CASE-J Ex). In CASE-J Ex, the primary end point is a composite of CV events and the secondary endpoints are all-cause death and new-onset diabetes. After Committee's decision, 245 doctors agreed to participate in CASE-J Ex and 2236 patients (1141 with candesartan-based regimens and 1095 with amlodipine-based regimens) were re-enrolled. The baseline characteristics of CASE-J Ex participants were similar to CASE-J participants and still balanced well between candesartan and amlodipine. Recently, the interest of antihypertensive treatment has focused to differentiation of the effects of antihypertensive agents on the incidence of CV events as well as blood pressure lowering effect. CASE-J Ex will clarify the long-term effects of ARB and CCB on CV mortality and morbidity. Additionally, because the number of diabetic patients is increased, the evidences from CASE-J Ex will be valuable.
Authors:
Kenji Ueshima; Koji Oba; Shinji Yasuno; Akira Fujimoto; Tosiya Sato; Koshiro Fukiyama; Junichi Azuma; Toshio Ogihara; Takao Saruta; Kazuwa Nakao;
Related Documents :
10585814 - Amphotericin b lipid complex (ablc)-associated hypertension: case report and review.
3363164 - Fading of therapeutic effects of alprazolam in agoraphobia. case reports.
19176794 - The costs and benefits of automatic estimated glomerular filtration rate reporting.
18577634 - Voriconazole in the treatment of fungal eye infections: a review of current literature.
24874274 - Dupuytren's disease involving guyon's canal.
11820314 - Transretinal feeder vessel ligature in von hippel-lindau disease.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-09-13
Journal Detail:
Title:  Contemporary clinical trials     Volume:  30     ISSN:  1559-2030     ISO Abbreviation:  Contemp Clin Trials     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-22     Completed Date:  2009-03-24     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  101242342     Medline TA:  Contemp Clin Trials     Country:  United States    
Other Details:
Languages:  eng     Pagination:  97-101     Citation Subset:  IM    
Affiliation:
EBM Research Center, Kyoto University Graduate School of Medicine, Kyoto, Japan. k_ueshima@pbh.med.kyoto-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amlodipine / therapeutic use*
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Benzimidazoles / therapeutic use*
Blood Pressure
Calcium Channel Blockers / therapeutic use*
Cardiovascular Diseases / etiology,  prevention & control
Female
Humans
Hypertension / complications,  drug therapy*,  mortality
Japan
Male
Middle Aged
Tetrazoles / therapeutic use*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Calcium Channel Blockers; 0/Tetrazoles; 88150-42-9/Amlodipine; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Countering imbalanced datasets to improve adverse drug event predictive models in labor and delivery...
Next Document:  A collaborative approach to the recruitment and retention of minority patients with diabetes in rura...